| |
|
|
|
Akari Therapeutics  
|
|
1.7 0.07 (0.04%) |
10-22 16:00 |
|
Open: |
1.7 |
Pre close: |
1.63 |
Target:
|
2.13
|
|
High: |
1.7599 |
Low: |
1.62 |
Resistance:
|
1.83
1.99
|
|
Volume: |
224,959 |
Market Cap: |
58M |
Support:
|
1.56
1.30
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.70
 |
MACD |
MACD(12,26):
|
-0.01 |
|
MA(20): |
1.76  |
Signal(12,26,9): |
0.01 |
|
MA(100): |
1.92 |
Stochastic Oscillator |
%K(14,3):
|
11.02 |
|
MA(250): |
1.83 |
%D(3): |
15.10 |
|
Average Volume(K) |
3-Month: |
18072
|
52-Week |
High:
|
2.79 |
|
10-Days: |
17829 |
Low: |
0.87 |
|
RSI |
RSI(14):
|
46.61 |
Change(%): |
-4.0 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.967 |
Return on Equity (ttm) |
-2252.3 |
Shares Out. (M) |
33.87 |
|
EPS Est. Current Year |
-2.360 |
Return on Assets (ttm) |
-133.2 |
Shares Float (M) |
16.69 |
|
EPS Est. Next Year |
-3.110 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.85 |
|
EPS Est. Next Quarter |
-0.660 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
3.23 |
|
Forward EPS |
-0.100 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
272 |
|
Book Value (p.s.) |
0.100 |
EBITDA (p.s.) |
-0.616 |
P/E |
-1.76 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
17.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-20.39 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-7.36 |
P/CF |
-2.82 |
|
|
|
|
|
|
